Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.


Jun 12, 2018
Letter to the Senate Finance Committee leadership supporting the Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018.
Jun 7, 2018
The American Hospital Association and others support Senators Grassley and Feinstein of the Senate Judiciary Committee for their leadership and commitment to reducing out-of-control prescription dr
Jun 6, 2018
AHA letter to Energy and Commerce Committee Subcommittee on Health’s discussion draft, titled the “Pandemic and All-Hazards Preparedness Reauthorization Act of 2018.”
May 24, 2018
AHA responds to the Food and Drug Administration’s Medical Device Safety Action Plan, particularly with regard to advancing medical device cybersecurity.
May 23, 2018
AHA's comment on the CMS proposed rule to amend requirements that states assess their Medicaid fee-for-service provider payments to determine if they are sufficient to ensure beneficiary access to covered services.
May 22, 2018
AHA letter to Senators Alexander and Murray expressing support for the Senate Health, Education, Labor and Pensions Committee’s bipartisan reauthorization of the hospital and public health preparedness programs contained within S. 2852, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018.
May 22, 2018
AHA letter to Senators Isakson and Tester expressing support for S. 2372, the VA Maintaining Internal Systems and Strengthening Integrated Outside Networks Act of 2018 (VA MISSION Act of 2018).
May 22, 2018
AHA comments to HRSA regarding proposed rule that would further delay the effective date for implementing final regulations regarding the 340B Drug Pricing Program ceiling price and drug manufacturers’ civil monetary penalties (CMPs) for violations of the ceiling price.